Английская Википедия:Estradiol/estradiol enanthate
Шаблон:Short description Шаблон:Drugbox
Estradiol/estradiol enanthate (E2/E2-EN) is an injectable combination formulation of estradiol (E2), a short-acting estrogen, and estradiol enanthate (E2-EN), a long-acting estrogen, which was developed by Boehringer around 1960 for potential medical use but was never marketed.[1][2] It contained 1 mg E2 and 9 mg E2-EN in oil solution and was intended for administration by intramuscular injection.[1][2]
A single intramuscular injection of E2/E2-EN (1 mg/9 mg) has been found to result in a 10-fold increase in estradiol excretion on the 2nd day post-injection (due to the 1 mg short-acting E2 component).[1][2] Following this, estradiol excretion remained above the menstrual-cycle average for 10 days post-injection and did not return to baseline until the 24th day post-injection (due to the 9 mg long-acting E2-EN component).[1][2]
E2/E2-EN is similar to estradiol benzoate/estradiol phenylpropionate (brand name Dimenformon Prolongatum), another injectable combination medication of a shorter-acting estrogen (2.5 mg) and a longer-acting estrogen (10 mg).[1][2] In contrast to E2/E2-EN however, estradiol benzoate/estradiol phenylpropionate was marketed for medical use.[1][2]
See also
- Estradiol benzoate/estradiol phenylpropionate
- Estradiol benzoate/estradiol valerate/hydroxyprogesterone caproate
- List of combined sex-hormonal preparations
References
Шаблон:Estrogens and antiestrogens
Шаблон:Estrogen receptor modulators
Шаблон:Genito-urinary-drug-stub